Skin + Me is a technology company.
Skin + Me offers personalized skincare treatments designed by dermatologists to address various skin concerns such as acne and skin aging.
Skin + Me has raised $12.0M across 1 funding round.
Skin + Me has raised $12.0M in total across 1 funding round.
Skin + Me has raised $12.0M in total across 1 funding round.
Skin + Me's investors include Hyperplane, Octopus Ventures.
Skin + Me is a UK-based digital health and technology company specializing in personalized medical skincare solutions delivered through online dermatology consultations. It offers tailored prescription treatments for common skin concerns such as acne, rosacea, pigmentation, and skin aging, using clinically proven, prescription-only active ingredients that are inaccessible via traditional beauty retail. Their flagship product, the patented Daily Doser, dispenses precise doses of personalized formulations monthly, ensuring effective and adaptable skincare regimens designed by expert dermatologists and pharmacists. Skin + Me serves consumers seeking accessible, science-backed dermatological care remotely, addressing the problem of ineffective, one-size-fits-all skincare products and the lack of affordable, expert-led treatment options. The company has demonstrated strong growth, scaling rapidly since its launch in 2020 with millions of prescriptions delivered and expanding its product range to include cleansers and moisturizers tailored to complement their treatments[1][2][3][4][6][7].
Skin + Me was founded in 2018 by a team of dermatologists, pharmacists, and direct-to-consumer entrepreneurs united by the mission to democratize access to effective medical skincare. The idea emerged from extensive research revealing widespread consumer confusion and dissatisfaction with conventional skincare products and a desire to make dermatology expertise accessible and affordable. Early traction came from the launch of the Daily Doser in 2020, a unique technology that dispenses exact doses of personalized solutions, which helped the company rapidly build a loyal customer base and expand its treatment offerings to include rosacea and melasma. The company’s evolution has been marked by continuous innovation, including experimentation with 3D face scanning to optimize dosing and a commitment to integrating technology without replacing human medical expertise[1][2][3][4][5].
Skin + Me rides the wave of digital health innovation and personalized medicine, leveraging teledermatology and technology to disrupt traditional skincare and dermatology markets. The timing is favorable due to increasing consumer demand for personalized, effective skincare solutions and the growing acceptance of remote healthcare services. Market forces such as rising skin health awareness, the limitations of generic beauty products, and advances in digital diagnostics support their growth. By integrating patented dispensing technology and expert-led personalized prescriptions, Skin + Me influences the broader ecosystem by setting new standards for accessible, science-driven skincare and demonstrating the viability of combining medical expertise with direct-to-consumer digital platforms[1][3][4][5].
Looking ahead, Skin + Me is poised to expand its product portfolio and deepen its use of technology, potentially incorporating more advanced diagnostics like 3D scanning to further personalize dosing. The trend toward digital health and personalized medicine will continue to shape their journey, with increasing consumer expectations for tailored, effective treatments delivered conveniently. Their influence may grow as they pioneer a hybrid model combining medical rigor with consumer accessibility, potentially inspiring broader adoption of teledermatology and personalized skincare globally. Maintaining the balance between technological innovation and human medical oversight will be critical to sustaining trust and efficacy in this evolving landscape[1][3][5].
Skin + Me has raised $12.0M across 1 funding round. Most recently, it raised $12.0M Series B in February 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 1, 2023 | $12.0M Series B | Hyperplane, Octopus Ventures |